Pfizer Inc

Chart & Performance

D1W1MN

P/E

70.31

P/S

2.55

EPS

0.37

Div Yield, %

6.21%

Shrs. gr., 5y

-0.91%

Rev. gr., 5y

1.75%

Revenues

58.50b

-41.70%

Net income

2.12b

-93.25%

CFO

8.70b

-70.27%

Dividend

Jul 25, 20240.42 USD/sh

Earnings

Jan 28, 2025

Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

URL

https://www.pfizer.com/

IPO date

Jan 17, 1944

Employees

83,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	58,496,000 -41.70%	100,330,000 23.43%	81,288,000 93.97%
Cost of revenue	55,137,000	59,449,000	57,353,000
Unusual Expense (Income)
NOPBT	3,359,000	40,881,000	23,935,000
NOPBT Margin	5.74%	40.75%	29.44%
Operating Taxes	(1,114,000)	3,328,000	1,852,000
Tax Rate		8.14%	7.74%
NOPAT	4,473,000	37,553,000	22,083,000
Net income	2,119,000 -93.25%	31,372,000 42.74%	21,979,000 213.09%
Dividends	(9,247,000)	(8,983,000)	(8,729,000)
Dividend yield	5.63%	3.06%	2.59%
Proceeds from repurchase of equity		(2,000,000)
BB yield		0.68%
Debt
Debt current	10,346,000	2,945,000	2,241,000
Long-term debt	64,164,000	34,522,000	37,267,000
Deferred revenue			16,493,000
Other long-term liabilities	27,241,000	26,203,000	9,744,000
Net debt	46,050,000	(334,000)	(13,087,000)
Cash flow
Cash from operating activities	8,700,000	29,267,000	32,580,000
CAPEX	(3,907,000)	(3,236,000)	(2,711,000)
Cash from investing activities	(32,278,000)	(15,783,000)	(22,546,000)
Cash from financing activities	26,066,000	(14,834,000)	(9,816,000)
FCF	(1,117,000)	36,161,000	21,101,000
Balance
Cash	12,690,000	22,732,000	31,069,000
Long term investments	15,770,000	15,069,000	21,526,000
Excess cash	25,535,200	32,784,500	48,530,600
Stockholders' equity	111,144,000	118,084,000	98,232,000
Invested Capital	162,877,800	122,618,500	90,901,400
ROIC	3.13%	35.18%	23.69%
ROCE	1.78%	26.13%	17.12%
EV
Common stock shares outstanding	5,709,000	5,733,000	5,708,000
Price	28.79 -43.81%	51.24 -13.23%	59.05 60.42%
Market cap	164,362,110 -44.05%	293,758,920 -12.85%	337,057,400 62.58%
EV	210,686,110	293,680,920	324,232,400
EBITDA	9,649,000	45,945,000	29,126,000
EV/EBITDA	21.84	6.39	11.13
Interest	2,209,000	1,238,000	1,291,000
Interest/NOPBT	65.76%	3.03%	5.39%